- Home
- BNTC vs DBL Comparison
BNTC vs DBL Comparison
Compare BNTC & DBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNTC
- DBL
- Stock Information
- Founded
- BNTC 1995
- DBL 2011
- Country
- BNTC United States
- DBL United States
- Employees
- BNTC N/A
- DBL N/A
- Industry
- BNTC Biotechnology: Pharmaceutical Preparations
- DBL
- Sector
- BNTC Health Care
- DBL
- Exchange
- BNTC Nasdaq
- DBL Nasdaq
- Market Cap
- BNTC 366.6M
- DBL 296.0M
- IPO Year
- BNTC N/A
- DBL N/A
- Fundamental
- Price
- BNTC $12.89
- DBL $15.30
- Analyst Decision
- BNTC Strong Buy
- DBL
- Analyst Count
- BNTC 6
- DBL 0
- Target Price
- BNTC $23.83
- DBL N/A
- AVG Volume (30 Days)
- BNTC 234.8K
- DBL 61.0K
- Earning Date
- BNTC 05-14-2025
- DBL 01-01-0001
- Dividend Yield
- BNTC N/A
- DBL 8.67%
- EPS Growth
- BNTC N/A
- DBL N/A
- EPS
- BNTC N/A
- DBL N/A
- Revenue
- BNTC N/A
- DBL N/A
- Revenue This Year
- BNTC N/A
- DBL N/A
- Revenue Next Year
- BNTC N/A
- DBL N/A
- P/E Ratio
- BNTC N/A
- DBL N/A
- Revenue Growth
- BNTC N/A
- DBL N/A
- 52 Week Low
- BNTC $7.05
- DBL $13.75
- 52 Week High
- BNTC $17.15
- DBL $15.70
- Technical
- Relative Strength Index (RSI)
- BNTC 50.13
- DBL 39.43
- Support Level
- BNTC $12.57
- DBL $15.27
- Resistance Level
- BNTC $13.88
- DBL $15.37
- Average True Range (ATR)
- BNTC 1.18
- DBL 0.10
- MACD
- BNTC 0.02
- DBL -0.02
- Stochastic Oscillator
- BNTC 62.63
- DBL 14.29
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
About DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.